How BMS Is Tackling Clinical Trial Diversity
Site Selection Is A Critical Component
Executive Summary
The company’s director of clinical trial diversity strategy, Lorena Kuri, talked to Scrip about how she became interested in trial diversity and what BMS is doing to increase it.
You may also be interested in...
Has There Been A Sea Change In Trial Diversity Efforts?
PhRMA partnered with Deloitte to produce a report that included a survey of 31 member companies indicating that most had made significant investments in improving clinical trial diversity.
Database In Works To Help Drugmakers Avoid Molecules That Trigger Immune Reactions
Individuals from pharma, biotech, technology and academia create shared database to facilitate development of therapeutic proteins that are unlikely to provoke immune reactions.
Novartis Looks To Take Its Diversity Show On The Road
Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.